2015: Speakers

Amanda Barry, Esq. is Associate General Counsel for Global Oral Care and Health Care at The Procter & Gamble Company.  She previously led attorneys in the pet care business prior to its divestiture by P&G.  She is a dual graduate of the University of Michigan for undergraduate and law school, and also has a Masters degree in Molecular Genetics from the University of Cincinnati.

Michael L. Fuller, Esq. is a partner in the San Diego office of Knobbe, Martens, Olson and Bear, L.L.P. He focuses on complex intellectual property issues for the biotechnology and high technology industries, including the area of bioinformatics. Mike currently oversees the prosecution of large portfolios of patent applications in a variety of technical areas, including cell phones, ultracapacitors, gene arrays, antibodies, and cancer therapeutics. He also handles due diligence projects for corporate acquisitions, and has successfully defended against many ex parte re-examinations filed against his client’s patents. Prior to joining Knobbe, Mike was co-founder and President of Intronics Computer Corporation, a company that specialized in the design and manufacture of printed circuit boards and personal computers. Mike speaks regularly on Intellectual Property issues relating to biotechnology and computer technology. He has been an adjunct professor of Biotechnology Law at the University of San Diego School of Law and is currently vice-chair of the U.S. Pharmaceutical and Biotechnology Committee for Intellectual Property Owners Association. He obtained his J. D. from the University of San Diego School of Law, and his Bachelor and Masters degrees in biology from U.C.L.A., specializing in molecular biology. His graduate work related to using computers to perform molecular modeling of apolipoproteins. He is admitted to the State Bar of California and the United States District Court for the Southern District of California.

Harry J. Guttman, PhD, JD is Senior Counsel at Calfee, Halter, Griswold LLP.  Harry has . has more than a decade of intellectual property law experience, helping clients capture, procure, protect, generate income from, and enforce their intellectual property. He represents a diverse clientele, including multinational and Fortune 500 companies, start-ups and universities. Harry recognizes that each client has unique needs and business challenges; he helps clients maximize value from intellectual property by structuring strategies to those unique criteria.  Harry has worked in numerous technical areas, including pharmaceuticals, biologics, biochemistry, immunology, microbes, stem cells, polymer/rubber chemistry, photochemistry, fuel cells, biofuels and bioproducts, among other chemical, biotechnology and alternative energy technologies. He has extensive experience in strategic patent portfolio development; U.S. and foreign patent application preparation and prosecution; freedom-to-operate, infringement and validity analysis; and other opinions of counsel tailored to address and protect client interests. He also has expertise in post-grant patent procedures (e.g., ex parte and inter partes re-examinations and reissue applications), patent landscape analyses, licensing transactions, due diligence investigations, FDA patent term extensions, and intellectual property audits.

Sarah Hesford is a Chartered Patent Attorney (UK), a European Patent Attorney, and a Senior Associate in the Patents group at Gill, Jennings & Every LLP in London.  Sarah graduated from Imperial College London with a degree in Biochemistry.  She also holds a certificate in Intellectual Property Law from Queen Mary, University of London.  Sarah has extensive experience drafting, filing, and prosecuting patent applications worldwide.  She had worked with technologies including genetic engineering, polynucleotide sequencing, cell and protein-based vaccines, stem cell therapies, personalized medicine and diagnostic assays, drug delivery, animal health and nutrition, agricultural technologies and plant variety rights.

Justin Levy, Esq. is a technology manager at the Center for Technology Commercialization within Cincinnati Children’s Hospital Medical Center. The office’s focus is to ensure that the technologies invented at Cincinnati Children’s Hospital can reach the public. Justin manages technologies coming from the Cancer and Blood Diseases Institute, the Heart Institute, Gastroenterology, Biomedical Informatics as well as many other divisions within the hospital. With the office, Justin assists in the filing and registration of the university’s intellectual property, the marketing of those technologies to companies or organizations and the negotiation of licensing agreements. He has previously worked as a licensing associate at Tulane University’s Office of Technology Transfer and Intellectual Property Development, a fellow at the New Orleans BioInnovation Center, assisting biotechnology startups in greater New Orleans, and as a fellow at the Tulane Center for Intellectual Property Law and Culture, assisting in the development of a web tool that can determine copyright status of any work anywhere in the

Muriel M. Liberto, PhD, Esq. is Of Counsel in Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.’s New York office specializing in the areas of biotechnology, pharmaceuticals, and medical devices. Muriel assists clients in all aspects of their patent strategy including patent drafting and procurement, patent portfolio management, IP due diligence, patentability and freedom-tooperate analyses. She has considerable experience in diverse areas including vaccines, oral and inhaled drug formulations, inhaler and insulin pump devices, pharmacogenomics, and surgical implants for bone repair. Prior to her practice in law, Muriel worked in breast cancer research, focusing on understanding the relationship between growth factors and hormones in regulating breast cancer cell proliferation for the identification of new molecular targets for the treatment and prevention of cancer. She also worked with a computational biology group at Columbia University developing methods for detecting genetic regulatory elements in DNA sequence data using supervised machine learning methods.

Duane C. Marks, Esq. is Patent Counsel at Eli Lilly & Co. Duane oversees IP strategy of large molecule assets for Eli Lilly’s bio-products business unit. Previously, Duane served as Patent Counsel for Roche Diagnostics’ professional diagnostic and sequencing solutions business units. Prior to joining Roche, Duane was an associate attorney for what is now Faegre Baker Daniels. Before becoming an attorney, Duane held the position of Lead Scientific Consultant and Application Scientist at Roche. Duane holds an M.S. in Biological Sciences (Purdue University) and is a summa cum laude graduate of Indiana University McKinney School of Law. Duane has lectured nationally, and internationally, on IP topics including Subject Matter Eligibility, the Safe Harbor of §271(e)(1), Induced Infringement, and the Doctrine of Equivalents.

Barbara Rudolph, Ph.D., Esq. is a partner in the Washington, DC office of Finnegan, Henderson, Farabow, Garrett and Dunner, LLP.  Ms. Rudolph has successfully litigated complex Abbreviated New Drug Application (ANDA) and biotechnology cases over the past twenty years.  She serves as lead counsel in pharmaceutical and biotechnology disputes and has extensive litigation experience in federal courts.  She has also argued appeals before the U.S. Court of Appeals for the Federal Circuit and authored an amicus brief submitted to the U.S. Supreme Court in a landmark biotechnology patent case directed to isolated BRCA genes.  Ms. Rudolph has defeated patent challenges brought by generic companies in cases involving blockbuster drugs such as Nuvigil®, Enbrel®, Effexor® XR, and Nolvadex®.  She also lectures regularly in the United States and abroad on various aspects of U.S. patent law, with particular emphasis on the challenges and opportunities faced by the biotechnology and pharmaceutical industries.

Lucy Samuels is a Chartered Patent Attorney (UK), a European Patent Attorney, and a Partner in the Patents group at Gill, Jennings & Every LLP in London. Lucy graduated from Cambridge University with an Honors Degree in Natural Sciences, specializing in Chemistry. Much of Lucy’s practice involves oppositions before the European Patent office, and she has handled over 200 opposition and appeal hearings. Lucy’s practice embraces a wide variety of technologies in the areas of chemistry and chemical engineering, including surfactants, enzymes, food products, personal care products, and industrial horticultural growth media.

Mike Venerable is managing director of digital, software and health tech at CincyTech and a member of the CincyTech investment committee. He evaluates investment opportunities, advises startup companies and helps them prepare to receive venture capital. Venerable has more than 20 years of experience as a software industry entrepreneur and executive. He was co-founder and CEO of Talus, a leading data warehouse consultancy, from 1993-1998. Talus was then acquired by Sagent Technology, where he led the company’s services organization through the company’s successful IPO in 1999. He has specific experience in raising angel and venture capital, software business design and operation, software product management, business valuation, financial analysis and intellectual property. As an industry practitioner, Venerable is an expert on data warehouse design, business intelligence and analytic applications and software development processes. He has consulted with a variety of large organizations and software companies on product development and strategy. He is also the co-author of Data Warehouse Design Solutions (Wiley & Sons). Venerable has consulted on strategic product development initiatives for leading technology companies, including Siebel, Advent and Micros. Prior to joining CincyTech he was a managing director of Scius Capital, a NY-based boutique investment bank focused on early-stage capitalization and liquidity strategies for intellectual property owners in biosciences, information technology and industrial technology. At Scius he assisted in raising capital for companies in the life sciences, software and advanced manufacturing markets.

Peter S. White, PhD is the chair of the Division of Biomedical Informatics at the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center. In this role, he oversees informatics research and resources at both institutions, including academic, educational, data services, software development, and Research IT missions. Prior to 2014, Dr. White was research associate professor of pediatrics and section chief of Clinical Informatics at the University of Pennsylvania, and the recipient of the David Lawrence Altschuler Endowed Chair in Genomics and Computational Biology at The Children’s Hospital of Philadelphia (CHOP), where he served as director of the Center for Biomedical Informatics, faculty advisor of CHOP’s Bioinformatics Core Facility, co-director of CHOP’s Division of Genome Diagnostics, and co-director of the Bioinformatics in Translation section of the Penn/CHOP Clinical and Translational Science Award. In his research career, Dr. White has explored the development and application of novel approaches for disease gene discovery, including identifying causative genes for neuroblastoma, ADHD, autism, and congenital heart defects. He has also developed innovative approaches for integrating and disseminating clinical, phenotypic, and molecular data to researchers for promoting discovery and hypothesis validation. Dr. White has recently played a lead informatics role on a number of national data projects, including the NICHD Newborn Screening Translational Research Network, the NHLBI Bench to Bassinet Program, the NHGRI Clinical Sequencing and Exploratory Research and IGNITE Consortia, and the NIDCD Audiology and Genetics Database.